N-(硫代氨基甲酰)甘氨酸 | 51675-47-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(硫代氨基甲酰)甘氨酸
• 英文名称: 2-(carbamothioylamino)acetic acid
• 英文别名: 2-thioureidoacetic acid；thioureidoacetic acid；N-thiocarbamoyl-glycine；thioureido-acetic acid；4-thio-hydantoic acid；N-Thiocarbamoyl-glycin；Glycine, N-(aminothioxomethyl)-
• CAS: 51675-47-9
• 化学式: C₃H₆N₂O₂S
• mdl: MFCD00086896
• 分子量: 134.159
• InChiKey: KIESEUTUOQOHLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  N-(硫代氨基甲酰)甘氨酸 在 硫酸 作用下， 以 丙酮 为溶剂， 生成 2-硫代乙内酰脲
  参考文献：
  名称：

  Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds

  摘要：

  Somatic mutations of isocitrate dehydrogenase 1 (LDH1) at R132 are frequently found in certain cancers such as glioma. With losing the activity of wild-type IDH1, the R132H and R132C mutant proteins can reduce alpha-ketoglutaric acid (alpha-KG) to D-2-hydroxyglutaric acid (D2HG). The resulting high concentration of D2HG inhibits many alpha-KG-dependent dioxygenases, including histone demethylases, to cause broad histone hypermethylation. These aberrant epigenetic changes are responsible for the initiation of these cancers. We report the synthesis, structure activity relationships, enzyme kinetics, and binding thermodynamics of a novel series of 2-thiohydantoin and related compounds, among which several compounds are potent inhibitors of mutant IDH1 with K-i as low as 420 nM. X-ray crystal structures of IDH1(R132H) in complex with two inhibitors are reported, showing their inhibitor-protein interactions. These compounds can decrease the cellular concentration of D2HG, reduce the levels of histone methylation, and suppress the proliferation of stem-like cancer cells in BT142 glioma with IDH1 R132H mutation.

  DOI：

  10.1021/acs.jmedchem.5b00684
• 作为产物：
  描述：

  5-benzoyl-4-thio-hydantoic acid methyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 N-(硫代氨基甲酰)甘氨酸
  参考文献：
  名称：

  囊性纤维化患者具有多种有益副作用的多靶点CFTR调节剂：简化治疗方法†。

  摘要：

  囊性纤维化（CF）是一种由囊性纤维化跨膜电导调节剂（CFTR）突变引起的多器官疾病。除了由于粘液积聚引起的呼吸障碍外，病毒和细菌还会引发急性肺部恶化，从而加速疾病的进展和死亡率。随着患者年龄的增长，治疗的复杂性也随之增加，简化治疗方案代表了CF的关键优先事项之一。最近，我们报道了通过靶向F508del-CFTR和PI4KIIIβ从而“充当CFTR校正剂和广谱肠病毒（EV）抑制剂”的多目标化合物的发现，该化合物能够“杀死一颗鸟而杀死两只鸟”。从这些初步的结果开始，我们在此报告了铅到铅的优化和多维结构-活性关系（SAR）研究，该研究导致了化合物23a。该化合物显示出良好的抗病毒和F508del-CFTR校正能力，与lumacaftor的加性/协同作用，以及有希望的体外吸收，分布，代谢和排泄（ADME）特性。它在体内具有良好的耐受性，在主要的生物分布器官中没有急性毒性和组织学改变的迹象。

  DOI：

  10.1021/acs.jmedchem.9b01416

文献信息

• New 7-substituted quinolone antibacterial agents. The synthesis of 1-ethyl-1,4-dihydro-4-oxo-7-(2-thiazolyl and 4-thiazolyl)-3-quinolinecarboxylic acids
  作者：Townley P. Culbertson、John M. Domagala、Phred Peterson、Shannon Bongers、Jeffrey B. Nichols

  DOI：10.1002/jhet.5570240604

  日期：1987.11

  4-dihydro-4-oxo-7-(4-thiazolyl)-3-quinolinecarboxylic acids and 1-ethyl-1,4-dihydro-4-oxo-7-(2-thiazolyl)-3-quinolinecarboxylic acids were prepared. Also prepared was 10-[2-(aminomethyl)-4-thiazolyl]-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid. Analogs with basic amine substituents on the thiazole moiety were found to have antibacterial activity.

  一系列1-乙基-1,4-二氢-4-氧代-7-（4-噻唑基）-3-喹啉羧酸和1-乙基-1,4-二氢-4-氧代-7-（2-噻唑基制备）-3-喹啉羧酸。还制备了10- [2-（氨基甲基）-4-噻唑基] -9-氟-2,3-二氢-3-甲基-7-氧代-7 H-吡啶基[1,2,3- de ] [1 ，4]苯并恶嗪-6-羧酸。发现在噻唑部分具有碱性胺取代基的类似物具有抗菌活性。
• Ultrashort acting hypnotic barbiturates
  申请人：——

  公开号：US20020013330A1

  公开（公告）日：2002-01-31

  The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.

  该发明涉及一种新型化合物，可作为超短效催眠巴比妥酸盐使用。具体示例是巴比妥酸和硫巴比妥酸的衍生物。它们会被血液和组织酶迅速代谢，形成无催眠活性的极性代谢物，然后迅速被排泄。
• One-Pot Multicomponent Synthesis of Thiourea Derivatives in Cyclotriphosphazenes Moieties
  作者：Zainab Ngaini、Wan Sharifatun Handayani Wan Zulkiplee、Ainaa Nadiah Abd Halim

  DOI：10.1155/2017/1509129

  日期：——

  In this study, hexasubstituted thiourea was carried out via reaction of isothiocyanato cyclophosphazene intermediates with a series of aromatics amines and amino acids in a one-pot reaction system. The reaction was not as straightforward as typical thiourea synthesis. Six unexpected thiourea derivatives 3a–f were formed in the presence of cyclotriphosphazene moieties in good yields (53–82%). The structures

  在这项研究中，六取代硫脲是通过异硫氰酸根合环磷腈中间体与一系列芳香胺和氨基酸在一锅反应系统中反应进行的。该反应不像典型的硫脲合成那样直接。在环三磷腈部分的存在下，以良好的产率（53-82%）形成了六种意想不到的硫脲衍生物 3a-f。3a-f 的结构通过元素分析和 FTIR、1H、13C 和 31P NMR 光谱表征。讨论了在一锅反应系统中形成反向硫脲的发生。还讨论了合成的硫脲 3a-b 与预测的苯基硫脲 5a-b 和目标 4a 与酶烯酰 ACP 还原酶 (FabI)​​ 的可能结合相互作用。
• Thiazole derivatives which are angiotensin II receptor antagonists,
  申请人：Laboratoires UPSA

  公开号：US05192781A1

  公开（公告）日：1993-03-09

  The present invention relates to the derivatives of formula (I): ##STR1## and their addition salts, and to their use in therapeutics, especially for the treatment of cardiovascular diseases and in particular for the treatment of hypertension and cardiac insufficiency.

  本发明涉及公式（I）的衍生物：##STR1##及其加合盐，以及它们在治疗学中的应用，特别是用于治疗心血管疾病，尤其是用于治疗高血压和心力衰竭的治疗。
• Synthesis and Biological Activity of Aminoguanidine and Diaminoguanidine Analogues of the Antidiabetic/Antiobesity Agent 3-Guanidinopropionic Acid
  作者：Valerie A. Vaillancourt、Scott D. Larsen、Steven P. Tanis、Jeffery E. Burr、Mark A. Connell、Michele M. Cudahy、Bruce R. Evans、Peter V. Fisher、Paul D. May、Martin D. Meglasson、Deborah D. Robinson、F. Craig Stevens、John A. Tucker、Thomas J. Vidmar、Jen H. Yu

  DOI：10.1021/jm000094n

  日期：2001.4.1

  3-Guanidinopropionic acid (1) has been demonstrated both to improve insulin sensitivity and to promote weight loss selectively from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM). However, 1 has also been shown to be a substrate for both the creatine transporter and creatine kinase, leading to marked accumulation in muscle tissue as the corresponding N-phosphate. The corresponding aminoguanidine analogue 2 was recently discovered to retain the antidiabetic activity of 1 while being markedly less susceptible to creatine-like metabolism, suggesting that it should have less potential to accumulate in muscle. Further structural modification of 2 was undertaken to investigate whether the antidiabetic potency could be augmented while maintaining resistance to creatine-like metabolism. Modifications such as a-alkylation, homologation, and bioisosteric replacement of the aminoguanidine all were detrimental to antidiabetic activity. However, the simple regioisomeric aminoguanidinoacetic acid 9 and diaminoguanidinoacetic acid-analogue 7 were found to be equipotent to 2, leading eventually to the discovery of the significantly more potent diaminoguanidinoacetic acid regioisomers 52 and 53. Further attempts to modify the more active template represented by 52 led only to reductions in; antidiabetic activity. Each of the new active analogues displayed the same resistance to creatine-like metabolism as 2. Further testing of 7, 9, and 53 in obese diabetic ob;lob mice confirmed that weight loss is induced selectively from adipose tissue, similar to the lead 1. Administration of 53 to insulin-resistant rhesus monkeys led to reductions in both fasting and post-prandial plasma glucose levels with concomitant reductions in plasma insulin levels, suggesting that the compound improved the action of endogenous insulin. Compounds 7 and 53 were selected for further preclinical development.